Clear Cell Renal Cell Carcinoma

Last updated July 6, 2022

Key Points

Key Points

  • Kidney cancer will be diagnosed in 79,000 U.S. patients in 2022 and will account for 13,920 deaths.
  • Opportunities for extended survival and even durable disease control in the metastatic setting have recently appeared as novel classes of therapeutics, reshaping the trajectory of this cancer.
  • This rapid evolution has paved the way for this first set of comprehensive guidelines for treating metastatic clear cell renal cell carcinoma (ccRCC).

Diagnosis

...Diagnosis...

...ndation 1.1The diagnosis of metastatic clear cell...


...ecommendation 1.2Radiographic diagnosis of metas...


Treatment

...Tr...

...endation 2.1Select patients (see Pract...


....1Select patients with metastatic...


...First-Line Treatment


...dation 3.2All patients with metastatic cle...


....3Patients with favorable risk diseas...


...ndation 3.4Select patients with metasta...


...mendation 3.5The use of high dose int...


...tion 4.1Nivolumab or cabozantinib should be off...


...ndation 4.2Patients progressing on combination i...


...on 4.3Patients who progress after i...


Recommendation 4.4For patients on imm...


...ecommendation 5.1For patients with l...


...ion 5.2For patients undergoing complete metastasec...


...on 6.1.1Patients with symptomatic bone metast...


...n 6.1.2Patients with bone metastases f...


...6.1.3No recommendation regarding optimal sys...


...re 2. Second-Line or Greater T...


...Metastases-Directed Treatment...


...commendation 6.2.1Patients with brain met...


...ommendation 6.2.2No recommendation...


Recommendation 6.3Patients with metas...


...4. Special Patient Subty...


...CO believes that cancer clinical trials ar...